Clinical Trials for IO Biotech

Explore 8 clinical trials worldwide

Showing 1-8 of 8 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: IO Biotech

Clinical Trials (8)

NCT06163391
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
PHASE1Recruiting
40 participants
Started: May 1, 2024 · Completed: Oct 31, 2026
2 conditions1 sponsor7 locations
NCT05280314
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
PHASE2Recruiting
60 participants
Started: Dec 21, 2023 · Completed: Jan 31, 2027
2 conditions4 sponsors15 locations
NCT05977907
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
PHASE2Recruiting
15 participants
Started: Dec 14, 2023 · Completed: Oct 16, 2028
1 condition3 sponsors5 locations
NCT05912244
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
PHASE2Recruiting
43 participants
Started: Jun 9, 2023 · Completed: Jun 9, 2027
1 condition2 sponsors9 locations
NCT05843448
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
PHASE1Recruiting
30 participants
Started: Apr 19, 2023 · Completed: Dec 31, 2026
4 conditions3 sponsors1 location
NCT05120271
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
PHASE1/PHASE2Active, not recruiting
7 participants
Started: Oct 26, 2022 · Completed: Dec 31, 2042
4 conditions3 sponsors8 locations
NCT05155254
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
PHASE3Active, not recruiting
407 participants
Started: May 17, 2022 · Completed: Sep 30, 2027
2 conditions3 sponsors112 locations
NCT05077709
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
PHASE2Active, not recruiting
63 participants
Started: Feb 14, 2022 · Completed: Nov 30, 2024
3 conditions5 sponsors21 locations